Pierre Geborek

Medicin och livsvetenskap

1. 13-valent pneumococcal vaccine 5%
2. Adalimumab 6%
3. Ankylosing Spondylitis 6%
4. Antibodies 7%
5. Antibody Formation 11%
6. Antirheumatic Agents 17%
7. Arthritis 26%
8. Biological Products 17%
9. Cartilage 5%
10. Cartilage Oligomeric Matrix Protein 8%
11. Cohort Studies 10%
12. Conjugate Vaccines 17%
13. Cost-Benefit Analysis 6%
14. Costs and Cost Analysis 5%
15. Cytidine Deaminase 5%
16. Etanercept 24%
17. Hand 5%
18. Health 5%
19. Hydroxychloroquine 5%
20. Infliximab 25%
21. Joints 11%
22. Knee 5%
23. Knee Joint 6%
24. Methotrexate 24%
25. Observational Studies 8%
26. Pharmaceutical Preparations 8%
27. Pneumococcal Vaccines 17%
28. Psoriatic Arthritis 11%
29. Quality-Adjusted Life Years 10%
30. Registries 7%
31. Rheumatic Diseases 16%
32. Rheumatoid Arthritis 100%
33. Rheumatology 8%
34. Rituximab 6%
35. Spondylarthritis 5%
36. Spondylarthropathies 6%
37. Sulfasalazine 5%
38. Sweden 31%
39. Synovial Fluid 16%
40. Systemic Scleroderma 5%
41. Systemic Vasculitis 5%
42. Therapeutics 13%
43. Tumor Necrosis Factor Inhibitors 36%
44. Tumor Necrosis Factor-alpha 15%
45. Vaccination 12%